Biohit Oyj Press Release May 18, 2016 at 9:30 am local time (EEST)
Biohit Oyj and Pooyandegan Pezeshki Pardis (3P) have signed an agreement for the distribution of the Biohit Unified GastroPanel® test in Iran.
GastroPanel® innovation is a stomach health test. The test is performed from a blood sample and designed for diagnosis of Helicobacter pylori infection and atrophic gastritis, irrespective whether caused by H. pylori infection or autoimmune disease. The test also enables to assess whether the patient is at risk for gastric or esophageal cancer, peptic ulcer disease or malabsorption of vitamin B12, calcium or iron. Among dyspeptic patients, GastroPanel® helps identifying the patients who need further examinations. GastroPanel® consists of four biomarkers: Pepsinogen I and II, Gastrin-17 and H. pylori -antibodies. In the unified GastroPanel® test, the reaction conditions and solutions are uniform, which makes the test fast and easy to perform in the laboratory.
CEO Ali Amari Allahyari, Pooyandegan Pezeshki Pardis: ‘We have signed a distributor agreement with the Finnish Healthcare company Biohit Oyj, to market, distribute and sell GastroPanel® test in Iran, where gastric cancer is a particularly common disease.'
CEO Semi Korpela, Biohit Oyj: ‘Iran is a high-incidence country for gastric cancer. We are starting now a co-operation with Iranian company Pooyandegan Pezeshki Pardis sharing our mission to improve clinical practices through innovations. The process for registration of the unified GastroPanel®-test in Iran has been initiated.’
Additional information on GastroPanel® test can be found in the attachment.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
Pooyandegan Pezeshki Pardis in brief
Pooyandegan Pezeshki Pardis (3P) is an Iranian company, designing, developing, manufacturing and selling medical devices. In 3P we believe in innovation and creativity along with the highest quality and focus to offer the best products and services to our customers. The company’s headquarters is located in Tehran. www.3pardis.com